Eledon Pharmaceuticals
ELDN
34 hedge funds and large institutions have $89M invested in Eledon Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
62% more funds holding
Funds holding: 21 → 34 (+13)
1% more capital invested
Capital invested by funds: $88.4M → $89M (+$589K)
342.46% less ownership
Funds ownership: 400.59% → 58.13% (-342%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$16.8M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$5.28M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.21M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.77M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.58M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.72M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.23M |
| 4 |
O
OrbiMed
New York
|
-$1.1M |
| 5 |
Morgan Stanley
New York
|
-$495K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Morgan Stanley
New York
| $124K | -$495K | -32,777 | -74% |
|
27
Citigroup
New York
| $23K | +$32.7K | +2,166 | New |
|
28
Rockefeller Capital Management
New York
| $17K | – | – | – |
|
|
CSS
29
Cubist Systematic Strategies
Stamford,
Connecticut
| $11K | +$15.1K | +1,000 | New |
|
|
SWM
30
Spire Wealth Management
Mclean,
Virginia
| $4K | +$5.28K | +350 | New |
|
31
UBS Group
Zurich,
Switzerland
| $1K | +$830 | +55 | New |
|
32
Wells Fargo
San Francisco,
California
| $1K | +$1.28K | +85 | +1,063% |
|
|
SCM
33
Stonepine Capital Management
Bend,
Oregon
| – | -$2.58M | -167,333 | Closed |
|
|
MS
34
Maven Securities
St Helier,
Jersey
| – | -$1.72M | -111,555 | Closed |
|
|
ACM
35
Asymmetry Capital Management
San Francisco,
California
| – | -$1.23M | -80,069 | Closed |
|
|
O
36
OrbiMed
New York
| – | -$1.1M | -73,650 | Closed |
|
|
TRCT
37
Tower Research Capital (TRC)
New York
| – | -$40K | -2,598 | Closed |
|
38
Bank of America
Charlotte,
North Carolina
| – | -$16K | -1,020 | Closed |
|
ELDN Hedge Fund Activity: Q1 2021 in Review
34 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2021, worth a combined $89M — up 0.67% from $88.4M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ELDN positions and 6 closed out — a net gain of 13 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $16.8M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $2.58M sold.
- 34 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $89M of Eledon Pharmaceuticals stock for Q1 2021, up 0.67% quarter-over-quarter.
- 19 funds opened new Eledon Pharmaceuticals positions in Q1 2021 and 6 closed out, a net change of +13 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2021 was EcoR1 Capital, an estimated $16.8M added.
- The largest Eledon Pharmaceuticals seller in Q1 2021 was Stonepine Capital Management, an estimated $2.58M sold.
Based on aggregated 13F filings for Q1 2021.